This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

42/100

✓ Peer-reviewed alzhub usefulness score 42 out of 100. Disease mechanisms

Topic: Brain proteins, microglia and lab models

It has been demonstrated to have neuroprotective effects in cellular models of neurodegenerative diseases; however, its precise mechanism of action in alleviating tau pathology in Alzheimer's disease (AD), as well as its potential to improve cognitive deficits in animal models, has not yet been elucidated. Results We found that SSc significantly relieved spatial memory impairment and alleviated the pathological hallmarks of AD-like tau, such as excessive tau phosphorylation and oxidative stress, in AAV-hTau-injected mice. Conclusions Our results suggest that SSc treatment ameliorates cognitive deficits and related tau pathological features in the hTau AD mouse model.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Chen, D., Li, R., She, F., Chen, J., Cho, S. M., Yang, B., et al. (2025). Saikosaponin C ameliorates tau-related pathology by modulating oxidative stress and MAPK axis in Alzheimer's disease. Journal of Ethnopharmacology. https://doi.org/10.1016/j.jep.2025.120221

Vancouver

Chen D, Li R, She F, Chen J, Cho SM, Yang B, et al. Saikosaponin C ameliorates tau-related pathology by modulating oxidative stress and MAPK axis in Alzheimer's disease. Journal of Ethnopharmacology. 2025. doi:10.1016/j.jep.2025.120221. PMID: 40588144.

BibTeX

@article{chen2025-40588144,
  author  = {Chen, Dongmei and Li, Ruomeng and She, Fei and Chen, Jiawen and Cho, Sang Min and Yang, Bohyun and Tian, Yuan and Guan, Le and others},
  title   = {{Saikosaponin C ameliorates tau-related pathology by modulating oxidative stress and MAPK axis in Alzheimer's disease}},
  journal = {Journal of Ethnopharmacology},
  year    = {2025},
  doi     = {10.1016/j.jep.2025.120221},
  pmid    = {40588144},
  url     = {https://doi.org/10.1016/j.jep.2025.120221}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.

Key findings

It has been demonstrated to have neuroprotective effects in cellular models of neurodegenerative diseases; however, its precise mechanism of action in alleviating tau pathology in Alzheimer's disease (AD), as well as its potential to improve cognitive deficits in animal models, has not yet been elucidated.
Results We found that SSc significantly relieved spatial memory impairment and alleviated the pathological hallmarks of AD-like tau, such as excessive tau phosphorylation and oxidative stress, in AAV-hTau-injected mice.
Conclusions Our results suggest that SSc treatment ameliorates cognitive deficits and related tau pathological features in the hTau AD mouse model.

Why it matters

In mice injected with human tau, saikosaponin C relieved spatial memory impairment and reduced excessive tau phosphorylation and oxidative stress. These are animal results, and the authors conclude only that saikosaponin C ameliorates cognitive deficits and tau pathology in this mouse model.

Study details

Evidence strengthLow

How this study scored 42/100

Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomised / blinded because the record does not state it.

Component	Points	Why
Journal tier	7 / 10	Tier 3 — peer-reviewed journal (Journal of Ethnopharmacology)
Journal's citation record	3 / 4	Journal of Ethnopharmacology: journal h-index 306 (OpenAlex, 2026-10-29)
Study design	0 / 12	No study design recorded — scores zero, not guessed (not stated in the record — scored 0)
Strength of evidence	1 / 5	Rated “low” in our summary
Peer-review validation	10 / 10	Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent	4 / 5	2025 — within 3 year(s) of the newest study here
Sample size	0 / 4	Participant count not stated — scores zero (not stated in the record — scored 0)
Effect reported	0 / 3	No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people	0 / 3	Not stated whether this was studied in people — scores zero (not stated in the record — scored 0)
Randomised / blinded	0 / 2	No randomisation or blinding stated — scores zero (not stated in the record — scored 0)
Times cited	2 / 7	Cited 6 times (OpenAlex, 2026-10-10)
Citations per year	1 / 5	2.0 citations a year over 3 year(s) since 2025
Impact for its field and year	3 / 6	Cited 3.3× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here	0 / 6	No other study in this library cites it
Still being cited	1 / 4	Cited 6 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record	2 / 4	Last-listed author Tae Ho Lee: h-index 42 (OpenAlex, whole career)
Institution's track record	3 / 3	Harvard University: institution h-index 3,235 (OpenAlex)
Multi-centre collaboration	1 / 3	OpenAlex lists 3 institution(s) in 2 countries
Indexed in PubMed	2 / 2	Indexed in PubMed (PMID 40588144)
Free to read	2 / 2	Free to read
Total	42 / 100	—

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here.

Related studies in Disease mechanisms

Also tagged “tdp-43”

1,150 studies in the library carry the topic tag “tdp-43”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 1,150 tagged studies.

Similar studies

More on Disease mechanisms

See all studies in Disease mechanisms →